ATE397448T1 - Verwendung von 4-(2-fluorophenyl)-6-methyl-2-(1- piperazinyl)thieno(2,3-d)pyrimidine zur behandlung von harninkontinenz - Google Patents

Verwendung von 4-(2-fluorophenyl)-6-methyl-2-(1- piperazinyl)thieno(2,3-d)pyrimidine zur behandlung von harninkontinenz

Info

Publication number
ATE397448T1
ATE397448T1 AT03702713T AT03702713T ATE397448T1 AT E397448 T1 ATE397448 T1 AT E397448T1 AT 03702713 T AT03702713 T AT 03702713T AT 03702713 T AT03702713 T AT 03702713T AT E397448 T1 ATE397448 T1 AT E397448T1
Authority
AT
Austria
Prior art keywords
thieno
piperazinyl
fluorophenyl
pyrimidine
methyl
Prior art date
Application number
AT03702713T
Other languages
English (en)
Inventor
David Cavalla
Robert William Gristwood
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE397448T1 publication Critical patent/ATE397448T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03702713T 2002-01-31 2003-01-29 Verwendung von 4-(2-fluorophenyl)-6-methyl-2-(1- piperazinyl)thieno(2,3-d)pyrimidine zur behandlung von harninkontinenz ATE397448T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202265.5A GB0202265D0 (en) 2002-01-31 2002-01-31 New therapeutic use

Publications (1)

Publication Number Publication Date
ATE397448T1 true ATE397448T1 (de) 2008-06-15

Family

ID=9930142

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03702713T ATE397448T1 (de) 2002-01-31 2003-01-29 Verwendung von 4-(2-fluorophenyl)-6-methyl-2-(1- piperazinyl)thieno(2,3-d)pyrimidine zur behandlung von harninkontinenz

Country Status (14)

Country Link
US (1) US7220748B2 (de)
EP (1) EP1469853B1 (de)
JP (1) JP2005516977A (de)
KR (1) KR20040081479A (de)
CN (1) CN1279915C (de)
AT (1) ATE397448T1 (de)
AU (1) AU2003205836B2 (de)
BR (1) BR0307369A (de)
CA (1) CA2474851A1 (de)
DE (1) DE60321445D1 (de)
ES (1) ES2307896T3 (de)
GB (1) GB0202265D0 (de)
PT (1) PT1469853E (de)
WO (1) WO2003063873A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
US20040147510A1 (en) * 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
EP1795196A3 (de) * 2003-04-04 2008-02-06 Dynogen Pharmaceuticals, Inc. Verfahren zur Behandlung von Erkrankungen der unteren Harnwege
DE602004007225T2 (de) 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham Methode zur behandlung von erkrankungen der unteren harnwege
US7643420B2 (en) 2005-03-11 2010-01-05 Broadcom Corporation Method and system for transmission control protocol (TCP) traffic smoothing
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
FR2895259B1 (fr) * 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044854A1 (en) * 1990-07-19 1992-01-20 Hong-I Chen Method for preventing or treating urinary incontinence
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence

Also Published As

Publication number Publication date
CA2474851A1 (en) 2003-08-07
DE60321445D1 (de) 2008-07-17
ES2307896T3 (es) 2008-12-01
EP1469853A1 (de) 2004-10-27
WO2003063873A1 (en) 2003-08-07
EP1469853B1 (de) 2008-06-04
US20050222162A1 (en) 2005-10-06
CN1625402A (zh) 2005-06-08
US7220748B2 (en) 2007-05-22
PT1469853E (pt) 2008-06-24
KR20040081479A (ko) 2004-09-21
AU2003205836B2 (en) 2006-06-29
GB0202265D0 (en) 2002-03-20
CN1279915C (zh) 2006-10-18
BR0307369A (pt) 2004-12-14
JP2005516977A (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
ATE365551T1 (de) Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis
ATE433978T1 (de) 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
ATE359079T1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
BRPI0516242A (pt) compostos tieno-pirimidina tendo atividade fungicida
GB2398781B (en) Kinase inhibitors
HK1072254A1 (en) Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
EP1513821A4 (de) Proteinkinaseinhibitoren
BR0313968A (pt) Derivados de heteroaril nitrila
ATE401909T1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
EP1764092A3 (de) Therapeutische strategien für die prävention und behandlung der alzeheimer-krankheit
ATE397448T1 (de) Verwendung von 4-(2-fluorophenyl)-6-methyl-2-(1- piperazinyl)thieno(2,3-d)pyrimidine zur behandlung von harninkontinenz
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60314730D1 (de) Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
MXPA04003755A (es) Endoprotesis vasculares.
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60221275D1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
ATE388941T1 (de) Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
ATE390137T1 (de) Verwendung von pyridin-2,4-dicarbons urediamiden und pyrimid in-4,6-dicarbons urediamiden zur selektiven inhibierung von kollagenasen
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DE60219616D1 (de) Verwendung von 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl) Thieno (2,3-D)Pyrimidin zur Schmerzbehandlung
DE60008400D1 (de) Triazolopyrimidinderivate
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
BR0312511A (pt) 4- (2-fluorofenil)-6-metil-2- (1-piperazinil) tieno [2,3-d] pirimidina no tratamento de distúrbio funcional dos intestinos
WO2002085871A3 (en) Serotonergic agents with long-acting in vivo effects

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties